Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer

Purpose of review The present review describes the current role of metabolic imaging techniques such as multiparametric MRI (mpMRI), magnetic resonance spectroscopic imaging (MRSI), hyperpolarized MRSI, and positron emission tomography (PET) in the diagnosis of primary prostate cancer, surveillance of low-grade disease, detection of metastases, and evaluation of biochemical recurrence after therapy. Recent findings The natural history of prostate cancer ranges from indolent disease that is optimally monitored by active surveillance, to highly aggressive disease that can be lethal. Current diagnostic methods remain imperfect in noninvasively distinguishing between silent versus aggressive tumors. Hence, there is a high demand for noninvasive imaging techniques that offer insight into biological behavior of prostate cancer cells. Characterization of prostate cancer metabolism is a promising area to provide such insights. Summary Metabolic imaging may allow for greater detection and ultimately characterization of tumor based on aggressiveness and spread. Hence, it has the potential to monitor tumor activity, predict prognostic outcomes, and guide individualized therapies.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research

Related Links:

ConclusionsWe have successfully synthesized the radiotracer [18F]2 ‐amino‐4‐((2‐((3‐fluorobenzyl)oxy)benzyl)(2‐((3‐(fluoromethyl)benzyl)oxy)benzyl)amino)butanoic acid.In vitro experiments show a good affinity for both the human and rat ASCT ‐2. However, the tracer suffers from poorin vivo tumor uptake in the PC ‐3 model. Briefly, we present the first fluorine‐18 labelled derivative of compound V‐9302, a promising novel ASCT‐2 blocker used for inhibition of tumor growth.
Source: Journal of Labelled Compounds and Radiopharmaceuticals - Category: Biochemistry Authors: Tags: RESEARCH ARTICLE Source Type: research
Publication date: Available online 28 May 2020Source: Radiation Physics and ChemistryAuthor(s): Chen Ew-Jun, Tan Teik Hin, Chew Ming Tsuey
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research
ConclusionsIntegrated [68Ga]PSMA-11 PET/MRI provides a similarly high diagnostic performance for localization of recurrent PC as PET/CT. For the detection of local recurrences [68Ga]PSMA-11 PET/MRI is superior compared with [68Ga]PSMA-11 PET/CT.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
Carbon-ion radiotherapy (CIRT) for prostate cancer was initiated at Kanagawa Cancer Center in 2015. The present study analyzed the preliminary clinical outcomes of CIRT for prostate cancer.
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Conclusion: Our patient, diagnosed with recurrent prostate BCC after receiving a radical prostatectomy, responded to treatment with etoposide. Radical prostatectomy and radiotherapy should remain first-line therapy; however, etoposide may be an alternative second-line therapy when other options are not available. Consensus regarding treatment plans, and the molecular mechanisms behind prostate BBC, must be elucidated.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 25 May 2020Source: Practical Radiation OncologyAuthor(s): Abhishek A. Solanki, Bital Savir-Baruch, Stanley L. Liauw, Jeff Michalski, Jonathan D. Tward, Neha Vapiwala, Eugene J. Teoh, Lee P. Adler, Gerald L. Andriole, Laurence H. Belkoff, Daniel Burzon, Albert Chau, Paul Dato, Fenghai Duan, Michael Farwell, Stephen Fogelson, Peter Gardiner, Lucy Hanna, John M. Hoffman, Charles Intenzo
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Are prostate cancer biopsies reliably accurate? Not always. The most common method, called a systematic biopsy, sometimes misses tumors, and it can also misclassify cancer as being either more or less aggressive than it really is. During systematic biopsy, a doctor takes 12 evenly-spaced samples of the prostate, called cores, while looking at the gland with an ultrasound machine. A new method, called MRI-targeted biopsy, guides doctors to suspicious abnormalities in the prostate, and emerging evidence suggests that it’s better at detecting high-grade, aggressive tumors that need immediate treatment. These biopsies re...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Diagnosis Health Prostate Knowledge HPK Source Type: blogs
Whole-pelvis pencil beam scanning (PBS) proton therapy is utilized in both the intact and post-operative settings in patients with prostate cancer. As whole pelvis prostate radiotherapy has traditionally been delivered with standard photon beams, limited evidence and technical descriptions have been reported regarding the use of proton therapy. Here we present two robust three-field treatment planning approaches utilized to maximize target coverage in the presence of anatomic and delivery uncertainties.
Source: Medical Dosimetry - Category: Radiology Authors: Source Type: research
ConclusionsAn incidence of 0.1% in our study confirms the rarity of penile metastases of prostate cancer. Although rare, identification of prostate cancer penile metastases is important for appropriate treatment management and symptom ‐relief.
Source: Journal of Medical Imaging and Radiation Oncology - Category: Radiology Authors: Tags: Medical Imaging — Original Article Source Type: research
ung P Abstract PURPOSE: To report dosimetry, preliminary toxicity and health-related quality of life (HRQoL) outcomes of tumor-targeted dose-escalation delivered by integrated boost volumetric arc therapy (IB-VMAT) or MR-guided HDR brachytherapy (HDR) boost for prostate cancer. MATERIALS AND METHODS: Patients diagnosed with localized prostate cancer, with at least 1 identifiable intraprostatic lesion on multiparametric MRI (mpMRI) were enrolled in a prospective non-randomized phase II study. All patients received VMAT to the prostate alone (76 Gy in 38 fractions) plus a GTV boost: IB-VMAT (95Gy in 38 fraction...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
More News: Cancer | Cancer & Oncology | PET Scan | Prostate Cancer